188 related articles for article (PubMed ID: 7683344)
1. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.
Fong CJ; Sutkowski DM; Braun EJ; Bauer KD; Sherwood ER; Lee C; Kozlowski JM
J Urol; 1993 May; 149(5):1190-4. PubMed ID: 7683344
[TBL] [Abstract][Full Text] [Related]
2. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
Mol Cell Endocrinol; 1995 Mar; 109(1):105-11. PubMed ID: 7540569
[TBL] [Abstract][Full Text] [Related]
3. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
Lee C; Sutkowski DM; Sensibar JA; Zelner D; Kim I; Amsel I; Shaw N; Prins GS; Kozlowski JM
Endocrinology; 1995 Feb; 136(2):796-803. PubMed ID: 7530653
[TBL] [Abstract][Full Text] [Related]
4. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
5. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
Prostate; 1996 Mar; 28(3):182-94. PubMed ID: 8628721
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
[TBL] [Abstract][Full Text] [Related]
7. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
8. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
9. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):391-9. PubMed ID: 9449242
[TBL] [Abstract][Full Text] [Related]
10. Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor.
Li MT; Richter F; Chang C; Irwin RJ; Huang H
BMC Cancer; 2002 Jun; 2():16. PubMed ID: 12069693
[TBL] [Abstract][Full Text] [Related]
11. Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells.
Eskra JN; Kuiper JW; Walden PD; Bosland MC; Özten N
Eur J Cancer Prev; 2017 Jan; 26(1):71-77. PubMed ID: 26886237
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
13. Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions.
Fong CJ; Sherwood ER; Braun EJ; Berg LA; Lee C; Kozlowski JM
Prostate; 1992; 21(2):121-31. PubMed ID: 1384014
[TBL] [Abstract][Full Text] [Related]
14. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
[TBL] [Abstract][Full Text] [Related]
15. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E
Prostate; 1993; 23(3):213-23. PubMed ID: 7694266
[TBL] [Abstract][Full Text] [Related]
16. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
Ripple MO; Henry WF; Rago RP; Wilding G
J Natl Cancer Inst; 1997 Jan; 89(1):40-8. PubMed ID: 8978405
[TBL] [Abstract][Full Text] [Related]
17. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
18. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
Sherwood ER; Van Dongen JL; Wood CG; Liao S; Kozlowski JM; Lee C
Br J Cancer; 1998 Mar; 77(6):855-61. PubMed ID: 9528825
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.
Kim IY; Kim JH; Zelner DJ; Ahn HJ; Sensibar JA; Lee C
Endocrinology; 1996 Mar; 137(3):991-9. PubMed ID: 8603613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
